Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents
- PMID: 29168032
- DOI: 10.1007/s00520-017-3985-0
Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents
Abstract
Purpose: Patients with febrile neutropenia are a heterogeneous group with a minority developing serious medical complications. Outpatient management of low-risk febrile neutropenia has been shown to be safe and cost-effective. Scoring systems, such as the Multinational Association for Supportive Care in Cancer (MASCC) score and Clinical Index of Stable Febrile Neutropenia (CISNE), have been developed and validated to identify low-risk patients. We aimed to compare the performance of these two scores in identifying low-risk febrile neutropenic patients.
Methods: We performed a pooled analysis of patients presenting with febrile neutropenia to three tertiary cancer emergency centers in the USA, UK, and South Korea in 2015. The primary outcome measures were the occurrence of serious complications. Admission to an intensive care unit (ICU) and 30-day mortality were secondary outcomes. The predictive performance of each score was analyzed.
Results: Five hundred seventy-one patients presented with febrile neutropenia. With MASCC risk index, 508 (89.1%) were classified as low-risk febrile neutropenia, compared to 60 (10.5%) with CISNE classification. Overall, the MASCC score had a greater discriminatory power in the detection of low-risk patients than the CISNE score (AUC 0.772, 95% CI 0.726-0.819 vs. 0.681, 95% CI 0.626-0.737, p = 0.0024).
Conclusion: Both MASCC and CISNE scores have reasonable discriminatory value in predicting patients with low-risk febrile neutropenia. Risk scores should be used in conjunction with clinical judgment for the identification of patients suitable for outpatient management of neutropenic fever. Developing more accurate scores, validated in prospective settings, will be useful in facilitating more patients being managed in an outpatient setting.
Keywords: CISNE; Febrile neutropenia; MASCC; Risk score.
Similar articles
-
Application of the MASCC and CISNE Risk-Stratification Scores to Identify Low-Risk Febrile Neutropenic Patients in the Emergency Department.Ann Emerg Med. 2017 Jun;69(6):755-764. doi: 10.1016/j.annemergmed.2016.11.007. Epub 2016 Dec 29. Ann Emerg Med. 2017. PMID: 28041827
-
CISNE versus MASCC: Identifying low risk febrile neutropenic patients.Am J Emerg Med. 2020 Nov;38(11):2259-2263. doi: 10.1016/j.ajem.2019.09.016. Epub 2019 Nov 30. Am J Emerg Med. 2020. PMID: 31864874
-
Multinational association for supportive care in cancer (MASCC) versus clinical index of stable febrile neutropenia (CISNE): evaluation of predictive performance and clinical utility in patients with febrile neutropenia.Eur J Med Res. 2025 Aug 1;30(1):692. doi: 10.1186/s40001-025-02858-z. Eur J Med Res. 2025. PMID: 40745664 Free PMC article.
-
Accuracy of the Multinational Association of Supportive Care in Cancer (MASCC) and Clinical Index of Stable Febrile Neutropenia (CISNE) scores for predicting serious complications in adult patients with febrile neutropenia: A systematic review and meta-analysis.Crit Rev Oncol Hematol. 2020 May;149:102922. doi: 10.1016/j.critrevonc.2020.102922. Epub 2020 Mar 3. Crit Rev Oncol Hematol. 2020. PMID: 32244162
-
Current management of chemotherapy-induced neutropenia in adults: key points and new challenges: Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association Committee of Clinical Chemotherapy, China Anti-Cancer Association.Cancer Biol Med. 2020 Nov 15;17(4):896-909. doi: 10.20892/j.issn.2095-3941.2020.0069. Epub 2020 Dec 15. Cancer Biol Med. 2020. PMID: 33299642 Free PMC article. Review.
Cited by
-
Efficacy of prophylactic antibiotics for the prevention of neutropenic fever in patients with multiple myeloma receiving high-dose cyclophosphamide for stem cell mobilization.Ann Hematol. 2024 May;103(5):1601-1611. doi: 10.1007/s00277-023-05537-3. Epub 2024 Jan 25. Ann Hematol. 2024. PMID: 38267561 Free PMC article.
-
Validation of the Clinical Index of Stable Febrile Neutropenia (CISNE) model in febrile neutropenia patients visiting the emergency department. Can it guide emergency physicians to a reasonable decision on outpatient vs. inpatient treatment?PLoS One. 2018 Dec 31;13(12):e0210019. doi: 10.1371/journal.pone.0210019. eCollection 2018. PLoS One. 2018. PMID: 30596803 Free PMC article.
-
Ambulatory management of low-risk febrile neutropenia in adult oncological patients. Systematic review.Support Care Cancer. 2023 Nov 3;31(12):665. doi: 10.1007/s00520-023-08065-y. Support Care Cancer. 2023. PMID: 37921996 Free PMC article.
-
Remote Monitoring of Patients With Hematologic Malignancies at High Risk of Febrile Neutropenia: Exploratory Study.JMIR Form Res. 2022 Jan 25;6(1):e33265. doi: 10.2196/33265. JMIR Form Res. 2022. PMID: 35076403 Free PMC article.
-
Critically ill patients with cancer: A clinical perspective.World J Clin Oncol. 2020 Oct 24;11(10):809-835. doi: 10.5306/wjco.v11.i10.809. World J Clin Oncol. 2020. PMID: 33200075 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources